Influence of tumor thrombus morphology on the surgical complexity in renal cell carcinoma with inferior vena cava tumor thrombus: a single-center, large-sample study from China - Takeaways - MDSpire

Influence of tumor thrombus morphology on the surgical complexity in renal cell carcinoma with inferior vena cava tumor thrombus: a single-center, large-sample study from China

  • By

  • Xun Zhao

  • Zhuo Liu

  • Ji-yuan Chen

  • Wei Guo

  • Hong-xian Zhang

  • Xiao-jun Tian

  • Guo-liang Wang

  • Cheng Liu

  • Lu-lin Ma

  • Shu-dong Zhang

  • July 29, 2024

  • 0 min

Share

  • 1

    Renal cell carcinoma (RCC) often invades the renal vein and inferior vena cava, forming tumor thrombus in 4-10% of patients.

  • 2

    Radical nephrectomy and thrombectomy can achieve over 50% 5-year survival if the tumor and thrombus are completely removed.

  • 3

    Tumor thrombus morphology varies, with floating thrombus having gaps and filled thrombus completely obstructing the IVC.

  • 4

    Patients with filled morphology thrombus experienced longer surgery times and had larger tumor thrombus dimensions.

  • 5

    The study highlights the importance of thrombus morphology in determining surgical complexity and patient prognosis.

Original Source(s)

Influence of tumor thrombus morphology on the surgical complexity in renal cell carcinoma with inferior vena cava tumor thrombus: a single-center, large-sample study from China

  • by Xun Zhao, Zhuo Liu, Ji-yuan Chen, Wei Guo, Hong-xian Zhang, Xiao-jun Tian, Guo-liang Wang, Cheng Liu, Lu-lin Ma, Shu-dong Zhang

  • July 29, 2024

Related Content

Dana-Farber Research News 12.15.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.

  • by

  • December 15, 2025

  • 19 min
Predicting surgical outcomes in single-port robot-assisted partial nephrectomy: external validation and comparative analysis of PADUA, RENAL, and SPARE scores

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

  • November 5, 2025

  • 1 min